The YIM-Committee

Ellinor Görgen is a resident hematologist and oncologist at the University Hospital Cologne, Germany.

She is a member and study physician of the German CLL Study Group (GCLLSG) led by Barbara Eichhorst and formerly led by Michael Hallek. She is a (sub)investigator in several clinical trials. Her clinical focus lies on aggressive and indolent lymphoma. She is a deputy member of the study commission for education of the University of Cologne. Her current areas of research involve individualization of CLL treatment, patient-reported outcomes, infections in immunocompromised patients, AI in hematology and oncology, and impact of climate change on patients with hematological diseases. Most recently, she is working as coordinating physician for the large randomized, multicenter phase-III CLL18 trial led by Paula Cramer.

Adalgisa Condoluci, Attending Hematologist & Training Coordinator at Oncology Institute of Southern Switzerland and Institute of Oncology Research (Bellinzona, Switzerland)

Dr. Adalgisa Condoluci is a board-certified hematologist at the Oncology Institute of Southern Switzerland (IOSI), where she serves as attending physician and coordinates medical training. With a strong focus on lymphoproliferative diseases, she conducted postdoctoral research at Columbia University and currently leads translational research at the Institute of Oncology Research (IOR) in the Laboratory of Experimental Hematology led by Prof. Davide Rossi. She has contributed to international collaborative studies on CLL and is pursuing a PhD in Cancer Biology and Oncology at Università della Svizzera Italiana. Her research focuses on prognostication in indolent lymphoproliferative disorders and CLL. Her work bridges patient care and molecular science, with a strong commitment to education and mentoring.

Paul Hampel, Assistant Professor of Medicine in the Division on Hematology at Mayo Clinic. He also serves on the Medical Advisory Board for the CLL Society.

Within the Mayo Clinic Comprehensive Cancer Center, he is a member of the Advanced Clinical Trials and Translational Sciences Research Program, Lymphoid Malignancies Group, and Cell Therapy Group. Dr. Hampel’s clinical and research focus is CLL and Richter transformation. He is dedicated to improving outcomes for all patients with CLL through leading innovated clinical trials and is a recipient of the Robert A. Winn Excellence in Clinical Trials Award Program. His areas of active research involve resistance mechanisms to targeted therapeutics, including coevolution of the disease and immune microenvironment, and is principal investigator a trial evaluating a novel treatment combination for patients with Richter transformation.